MedPath

Effect of Glucosamine on Intraocular Pressure

Phase 3
Conditions
Intraocular Pressure Changes After Glucosamine Sulfate Consumption.
Interventions
Registration Number
NCT02306083
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

In this double blind clinical trial 92 patients suffering from rheumatoid arthritis are included. Those with the history of intraocular and corneal surgery, diabetic and heavy smokers are excluded from the study. Before starting the treatment all patients undergo complete ophthalmic exam, corneal biomechanical properties assessment by Ocular Response Analyzer (ORA) and corneal thickness measurement. Patients are randomly assigned to treatment and placebo groups. Those in the treatment groups receive glucosamine sulfate 1500 mg three times a day. Those in placebo arm receive alike capsule with the same schedule. At month 3 and 6 IOP(intraocular pressure), ORA and pachymetry would be checked again.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
41
Inclusion Criteria
  • History of rheumatoid arthritis based on ACR (American College of Rheumatology)FC(functional classes).
  • No history of using drugs tested in the study.
Exclusion Criteria
  • History of any kind of corneal surgery.
  • History of intraocular surgery.
  • History of diabetes mellitus.
  • Heavy smokers.
  • Unwillingness to participate in the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Administration of the PlaceboPlacebo three times a dayPlacebo three times a day.
Administration of the glucosamine sulfateglucosamine sulfate 1500 mg three times a dayglucosamine sulfate 1500 mg three times a day
Primary Outcome Measures
NameTimeMethod
Intraocular pressure changesuntil 6 months

: Goldmann applanation tonometry

Secondary Outcome Measures
NameTimeMethod
corneal biomechanical changesuntil 6 months

Ocular Response Analyzer (ORA)

Trial Locations

Locations (1)

Islamic Republic OF Iran

🇮🇷

Tehran, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath